Skip to content

Interventional study on the effect of Shatapushpa Arka for Managing Menstrual Cramps in Young Women Participants.

Clinical study to evaluate the effect of Shatapushpa Arka in the management of Primary Dysmenorrhea in young adult females. - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072983
Enrollment
30
Registered
2024-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea

Interventions

None listed

Sponsors

Rajiv Gandhi University of Health Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Single (unmarried), young adult females between 20 and 24 years of age. Subjects having regular menstrual cycles in the interval of 21–35 days and bleeding duration of 3-7 days. Subjects suffering from pain during menstruation for more than 2 consecutive menstrual cycles. Lower abdominal and pelvic pain associated with onset of menses. Onset of pain within 6–12 hours after onset of menses and pain lasting for 9–72 hours. Subjects of Grade 1, 2 and 3 on the Verbal Multidimensional Scoring (VMS) System.

Exclusion criteria

Exclusion criteria: Female subjects with known history of Secondary Dysmenorrhea, Pelvic pathology, endometriosis, tubercular endometritis, polycystic ovarian syndrome. Female subjects with known history of thyroid, pituitary and hypothalamic abnormalities, general diseases like tuberculosis, nephritis, diabetes and heart diseases. History of any other surgical and neurological condition or surgery resulting in Dysmenorrhea.

Design outcomes

Primary

MeasureTime frame
Reduction in spasmodic lower abdominal pain as assessed in VMSS. Timepoint: Mentruation related spasmodic lower abdominal pain relief within 3 days of administration of trial drug.

Secondary

MeasureTime frame
Reduction in Associated Symptoms of Primary Dysmenorrhea as assessed in CMSS.Timepoint: Relief within 3 days of administration of trial drug.

Countries

India

Contacts

Public ContactSharanya CB

SDMIAH BANGALORE

20a4406@sdmayurbangalore.in9741700359

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026